Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
177LuBetaBart in Advanced Solid Tumors
NCT07189871Phase 2Recruiting
- Sponsor
- Radiopharm Theranostics
- Start
- Feb 2026
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of 177Lu-BETABART in castration-resistant prostate cancer (CRPC), colorectal cancer (CRC), non-small cell lung cancer (NSCLC), ovarian cancer, Cervical Cancer (CC), sponsored by Radiopharm Theranostics. Started Feb 2026; status: recruiting.
02
Drugs
177Lu-BETABART
03
Conditions
castration-resistant prostate cancer (CRPC)colorectal cancer (CRC)non-small cell lung cancer (NSCLC)ovarian cancerCervical Cancer (CC)
Beyond the preview
Go deeper on NCT07189871.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07189871.